Dermatological complaints account for approximately 15% to 20% of all outpatient consultations seen by general practitioners, family physicians, and rural medical officers. Because many skin disorders present with erythematous, scaly macules or plaques, misdiagnosis is common — leading to improper prescription of high-potency topical corticosteroids and severe steroid-induced complications.
This clinical review outlines visual diagnostic keys to separate common dermatoses and provides safe prescribing algorithms.
How can a general practitioner distinguish chronic plaque psoriasis from nummular eczema? Psoriasis and eczema frequently overlap in presentation, but key morphological features and anatomical predilections allow definitive bedside diagnosis:
- Chronic Plaque Psoriasis:
- *Margins*: Sharply demarcated, well-circumscribed erythematous plaques.
- *Scale*: Thick, silvery-white, mica-like micaceous scale.
- *Distribution*: Extensor surfaces (elbows, knees, presacral region, scalp, umbilicus).
- *Diagnostic Signs*: Auspitz sign (pinpoint bleeding upon scraping scale) and Koebner phenomenon (lesions appearing at sites of minor trauma).
- *Nail Changes*: Pitting, oil-drop discoloration, subungual hyperkeratosis.
- Nummular (Discoid) Eczema:
- *Margins*: Ill-defined or fuzzy borders.
- *Surface*: Oozing, crusting, vesicular, excoriated; lacks thick silvery scale.
- *Distribution*: Flexural predilection or symmetrical lower extremities.
- *Symptoms*: Intense, unrelenting pruritus (much more severe than psoriasis).
**Diagnostic Warning**: If an itchy rash is oozing or weeping serous fluid, it is virtually always eczema or an infected dermatitis, not uncomplicated psoriasis.
What are the diagnostic signs of Tinea Incognito caused by topical steroid abuse? In India, widespread over-the-counter availability of fixed-dose combination creams (Clobetasol + Ofloxacin + Ornidazole + Terbinafine) has created an epidemic of **Tinea Incognito** and topical steroid-damaged skin:
- Loss of the classic sharp, active raised erythematous border seen in standard dermatophyte ringworm.
- Diffuse erythema with widespread follicular papules, pustules, and dermal atrophy.
- Marked rebound worsening within 48 to 72 hours whenever the patient stops applying the cream.
- Skin thinning, prominent telangiectasias, and violaceous striae in intertriginous areas.
Management Strategy: 1. Immediately counsel the patient to discontinue the steroid combination cream. 2. Warn them of the expected rebound erythema and itching over the following 7–14 days. 3. Prescribe oral systemic antifungals (e.g. Itraconazole 100 mg twice daily for 2–4 weeks) alongside topical Ciclopirox olamine or Luliconazole cream. 4. Provide non-sedating oral antihistamines (Levocetirizine or Bilastine) for symptomatic pruritus control.
How should high-potency topical corticosteroids be tapered to prevent severe rebound flaring? Abrupt cessation of high-potency steroids (Class I/II like Clobetasol propionate or Betamethasone dipropionate) triggers intense rebound vasodilation and inflammatory flare. Primary care clinicians must use a structured tapering ladder:
1. Step-Down Frequency: Transition from twice daily to once daily for 1 week, then to alternate days for 1 week.
2. Step-Down Potency: Switch from Class I (Clobetasol) to Class IV/V (Mometasone or Hydrocortisone butyrate).
3. Transition to Calcineurin Inhibitors: For facial, intertriginous, or chronic maintenance therapy, replace steroids with topical Tacrolimus (0.03%–0.1%) or Pimecrolimus.
4. Liberal Emollients: Instruct the patient to apply bland ceramide-based moisturizers within 3 minutes of bathing to repair the disrupted stratum corneum barrier.
To master bedside dermatological recognition and sexually transmitted infection management, explore the Certificate Course in Skin Diseases (CSD) and Certificate Course in Venereal Diseases (CVD).